Coexpression of Dopamine and Somatostatin Receptor Subtypes in Corticotroph Adenomas

Christiaan Bruin, AM Pereira, R.A. Feelders, JA Romijn, F Roelfsema, Diana Mooij, MO van Aken, Aart Jan Lelij, W.W. de Herder, S.W.J. Lamberts, Leo Hofland

Research output: Contribution to journalArticleAcademicpeer-review

92 Citations (Scopus)


Context: Previous studies have demonstrated the expression of somatostatin receptor subtypes (mainly sst(5)) and dopamine (DA) receptor subtypes (mainly D-2) in smaller series of human corticotroph adenomas. In line with these findings, sst5 and D-2-targeting agents have already been used clinically in patients with Cushing's disease (CD) and have shown promising results in subsets of patients. To what extent these receptor subtypes are coexpressed within individual adenomas, is not known however. Objective: The aim of the study was to investigate the (co-) expression of both sst and DA receptors in a large series of human corticotroph adenomas. Design: We performed in vitro analysis of corticotroph adenoma tissue obtained via transsphenoidal adenomectomy. Setting: The study was conducted at two university medical centers. Patients: Adenoma tissue from 30 patients with CD was analyzed in this study. Results: Analyzed by quantitative RT-PCR, D-2 and sst(5) were significantly (co-) expressed in the majority (60%) of adenomas, whereas 23% of adenomas only expressed D-2, but not sst(5). The remaining 17% of adenomas did not significantly express either sst(5) or D-2. Overall, expression of sst(1-4) and D-4 was low to nondetectable. Corticotroph adenomas with invasive growth invariably showed loss of sst(5) and D-2 expression. Autoradiography revealed clear D-2 and/or SS-14 binding in a subset of cases, which correlated well with their respective mRNA data. Conclusions: Sst(5) and especially D-2 are highly expressed in the majority of human corticotroph adenomas, with coexpression of sst(5) and D-2 being acommonphenomenon. These findings support the current studies with sst5 and D-2-targeting agents in patients with CD and highlight the rationale behind sst(5)-D-2 combination therapy. (J Clin Endocrinol Metab 94: 1118-1124, 2009)
Original languageUndefined/Unknown
Pages (from-to)1118-1124
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Issue number4
Publication statusPublished - 2009

Cite this